InVera Medical Receives FDA Clearance for Non-Thermal Chronic Venous Disease Device

Why It Matters

The clearance introduces a safer, more efficient alternative to thermal ablation, potentially expanding treatment access for the vast, underserved CVD population and reshaping office‑based venous procedures.

Key Takeaways

• FDA 510(k) clears InVera’s 5Fr helical‑coil catheter for CVD
• Device enables single‑dose anesthetic, speeding patient recovery
• Non‑thermal approach avoids burns, nerve injury, and glue implants
• Targets >120 million CVD patients; only 1% currently treated

Pulse Analysis

Chronic venous disease remains a massive, under‑treated health issue, affecting roughly one in four adults across the United States and Europe. Traditional thermal ablation techniques, while effective, involve multiple painful injections, risk skin and nerve damage, and often require extended recovery—factors that limit their suitability for office‑based labs. Non‑thermal options exist but can be cumbersome, painful, or rely on permanent glue implants, leaving a sizable treatment gap for the estimated 120 million patients who could benefit from a less invasive solution.

InVera Medical’s newly cleared Infusion Device tackles this gap with a novel 5Fr catheter featuring a helical coil that mechanically disrupts the vein’s inner media layer. This preparation enhances the uptake of sclerotherapy agents, allowing physicians to administer a single local‑anesthetic dose and achieve rapid procedural efficiency. Early pilot data spanning 12 months demonstrate strong safety profiles and consistent procedural outcomes, suggesting the technology can deliver comparable efficacy to thermal methods while reducing patient discomfort and downtime.

Regulatory approval in both the U.S. and EU positions InVera to capture a share of the fast‑growing non‑thermal segment of the superficial venous reflux market, which sees over one million procedures annually in the United States alone. By offering a non‑thermal, non‑implant alternative, the device could broaden the pool of patients eligible for office‑based treatment, accelerate adoption among vascular specialists, and ultimately drive higher treatment rates in a market where only a fraction of sufferers currently receive care. The dual clearance also signals confidence to investors and partners, paving the way for expanded commercial rollout and potential integration with emerging tele‑medicine venous care pathways.